2-[[3-Hexadecanoyloxy-2-(5-oxopentanoyloxy)propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 2-[[3-Hexadecanoyloxy-2-(5-oxopentanoyloxy)propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
• 化学式: C29H57NO9P+
• 分子量: 594.7
• InChiKey: RKIDALSACBQVTN-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  40
• 可旋转键数：
  30
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  125
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• MEDIUM-CHAIN FATTY ACYLS AND PHOSPHOLIPIDS AS BIOMARKERS FOR CARDIOVASCULAR DISEASES
  申请人：Eberhard-Karls-Universität Tübingen

  公开号：EP4043884A1

  公开（公告）日：2022-08-17

  The present invention relates to the use of lipid compounds comprising at least one medium chain fatty acid as biomarkers for diseases which are due to or accompanied by fatty acid oxidation disorder. The present invention furthermore relates to methods of assessing the risk to develop said diseases by determining the lipid compounds in samples.

  本发明涉及将包含至少一种中链脂肪酸的脂质化合物作为生物标志物，用于检测由脂肪酸氧化紊乱引起或伴随的疾病。本发明还涉及通过测定样本中的脂质化合物来评估罹患上述疾病风险的方法。
• Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
  申请人：MacRegen, Inc.

  公开号：US10426817B2

  公开（公告）日：2019-10-01

  The present disclosure provides apolipoprotein (apo) mimetics useful for the treatment of age-related macular degeneration (AMD) and other eye disorders. The apo mimetics can be peptides/polypeptides that mimic, e.g., the lipid-clearing action of apolipoproteins such as apoA-I and apoE. The apo mimetics can exert other beneficial effects, such as reduction of inflammation, oxidative stress and neovascularization. The apo mimetics can be used to treat any stages (including the early, intermediate and advance stages) of AMD, and any phenotypes of AMD, including geographic atrophy (GA) (including non-central GA and central GA) and neovascularization (NV) (including types 1, 2 and 3 NV). The apo mimetics can be used alone or in conjunction with other therapeutic agents, such as a complement inhibitor and/or an anti-angiogenic agent, to treat AMD, including atrophic AMD and neovascular AMD, and other eye disorders.

  本公开提供了可用于治疗老年性黄斑变性（AMD）和其他眼部疾病的载脂蛋白（apo）模拟物。载脂蛋白模拟物可以是模拟载脂蛋白（如载脂蛋白A-I和载脂蛋白E）清脂作用的肽/多肽。载脂蛋白模拟物还能发挥其他有益作用，如减少炎症、氧化应激和新生血管。载脂蛋白模拟物可用于治疗AMD的任何阶段（包括早期、中期和晚期），以及AMD的任何表型，包括地理萎缩（GA）（包括非中心性GA和中心性GA）和新生血管（NV）（包括1型、2型和3型NV）。载脂蛋白模拟物可单独使用，也可与其他治疗剂（如补体抑制剂和/或抗血管生成剂）联合使用，用于治疗AMD（包括萎缩性AMD和新生血管性AMD）和其他眼部疾病。
• Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases
  申请人：MacRegen, Inc.

  公开号：US10905770B2

  公开（公告）日：2021-02-02

  The present disclosure provides therapeutic agents for the treatment of age-related macular degeneration (AMD) and other eye disorders. One or more therapeutic agents can be used to treat any stages (including the early, intermediate and advance stages) of AMD, and any phenotypes of AMD, including geographic atrophy (including non-central GA and central GA) and neovascularization (including types 1, 2 and 3 NV). In some embodiments, the one or more therapeutic agents are or include an anti-dyslipidemic agent, an antioxidant, an anti-inflammatory agent, a complement inhibitor, a neuroprotector or an anti-angiogenic agent, or any combination thereof. In certain embodiments, the one or more therapeutic agents are or include an anti-dyslipidemic agent (e.g., an apolipoprotein mimetic or/and a statin). In some embodiments, the one or more therapeutic agents are mixed with, non-covalently associated with or covalently bonded to a cell-penetrating peptide (CPP), encapsulated in CPP-conjugated nanoparticles, micelles or liposomes, or modified (e.g., stapled, prenylated, lipidated or coupled to a small-molecule α-helix mimic) to acquire membrane-translocating ability. In certain embodiments, the one or more therapeutic agents are administered by eye drop.

  本公开提供了用于治疗老年性黄斑变性（AMD）和其他眼部疾病的治疗剂。一种或多种治疗剂可用于治疗AMD的任何阶段（包括早期、中期和晚期），以及AMD的任何表型，包括地理萎缩（包括非中心性GA和中心性GA）和新生血管（包括1型、2型和3型NV）。在某些实施方案中，一种或多种治疗剂是或包括抗血脂异常剂、抗氧化剂、抗炎剂、补体抑制剂、神经保护剂或抗血管生成剂，或它们的任意组合。在某些实施方案中，一种或多种治疗剂是或包括抗血脂异常剂（例如，载脂蛋白模拟物或/和他汀类药物）。在某些实施方案中，一种或多种治疗剂与细胞穿透肽（CPP）混合、非共价结合或共价键合，包封在CPP共轭的纳米颗粒、胶束或脂质体中，或进行修饰（例如，钉合、前酰化、脂质化或与小分子α-螺旋模拟物偶联）以获得膜转运能力。在某些实施方案中，一种或多种治疗剂通过滴眼液给药。
• OXIDIZED LIPID DETECTION
  申请人：Kratos Analytical Limited

  公开号：EP3105597B1

  公开（公告）日：2020-11-18
• PROCESS TO ACTIVATE EXTRACTS DERIVED FROM LIVING ORGANISMS USING LONG WAVE UV IRRADIATION AND COMPOSITIONS COMPRISING SAID ACTIVATED EXTRACT
  申请人：Gruber Florian

  公开号：US20100119613A1

  公开（公告）日：2010-05-13

  The present invention relates to a method for producing an extract which is capable of inducing an antioxidant stress response comprising the step of treating an extract from organic material with UV light, said extract being derived from a non-mammalian cell or a non-mammalian organism and said cell or organism being capable of synthesizing polyunsaturated fatty acids. Furthermore, an extract capable of inducing an antioxidant stress response produced in accordance with the inventive methods, in particular an extract capable of inducing an antioxidant stress response for the preparation of a cosmetic composition is disclosed. The present invention also relates to a cosmetic composition comprising the inventive extract obtainable by the method provided herein.